Kiniksa Pharmaceuticals Ltd Class A KNSA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if KNSA is a good fit for your portfolio.
News
-
Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024
-
Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart
-
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution
-
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
Trading Information
- Previous Close Price
- $16.88
- Day Range
- $16.56–17.15
- 52-Week Range
- $10.65–22.09
- Bid/Ask
- $16.91 / $17.69
- Market Cap
- $1.19 Bil
- Volume/Avg
- 375,954 / 369,142
Key Statistics
- Price/Earnings (Normalized)
- 92.46
- Price/Sales
- 4.49
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 0.19%
Company Profile
Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; Vixarelimab; and KPL-404.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 297
- Website
- https://www.kiniksa.com
Comparables
Valuation
|
Metric
|
KNSA
|
VRDN
|
CBAY
|
|---|---|---|---|
Price/Earnings (Normalized) | 92.46 | — | — |
Price/Book Value | 2.71 | 3.48 | 12.65 |
Price/Sales | 4.49 | 2,160.78 | 111.01 |
Price/Cash Flow | 101.59 | — | — |
Price/Earnings
KNSA
VRDN
CBAY
Financial Strength
|
Metric
|
KNSA
|
VRDN
|
CBAY
|
|---|---|---|---|
Quick Ratio | 3.58 | 17.93 | 10.70 |
Current Ratio | 4.34 | 18.26 | 10.96 |
Interest Coverage | — | −137.76 | −5.27 |
Quick Ratio
KNSA
VRDN
CBAY
Profitability
|
Metric
|
KNSA
|
VRDN
|
CBAY
|
|---|---|---|---|
Return on Assets (Normalized) | 8.64% | −42.76% | −30.06% |
Return on Equity (Normalized) | 10.14% | −82.42% | −51.97% |
Return on Invested Capital (Normalized) | 9.90% | −50.70% | −30.87% |
Return on Assets
KNSA
VRDN
CBAY
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rhghwpzr | Rmswh | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Qtsltyfj | Vsqmvyx | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Wpdshmvpf | Ghnyj | $98.1 Bil | |
MRNA
| Moderna Inc | Cxlmtjzlx | Xvyc | $39.1 Bil | |
ARGX
| argenx SE ADR | Ldmmcwd | Hvkz | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Ycxkcrw | Cpmh | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mfgfmgz | Fhzdbrj | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Qqpjkqlgr | Rwwwvm | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Xxqndvdxz | Rstsy | $12.5 Bil | |
INCY
| Incyte Corp | Wgqvprcfy | Rwbxnyj | $11.9 Bil |